DEK and acute myeloid leukemia: DEK has been shown to be upregulated in many malignant conditions, such as AML [1, 2, 11–13], retinoblastoma [14–16], glioblastoma [17], hepatocellular carcinoma [18], oral squamous cell carcinoma (SCC) [19], melanoma [20, 21], and urinary bladder cancer [22–26].